2020-02-28 04:00:32 阅读：298243
th adults and children, acco
rding to the results. The study
of 55 patients was presented at the American Society of Clin
ical Oncologys (ASCO) Annual Meeting on Sunday but it has not yet been peer reviewed, according to ASCO.
Seventy-six percent of patients with 17 different types of cancer had tumor shrinkage, and after 12 months, 79% of the responsive patients did not report cancer progression. That does not mean that it improved the lifespan
of or the quality of life for the cance
ents, as those were not the end results studied here. The company Loxo Oncology funded the study for its
drug, and i
ts stocks jumped by more than 40% by Monday, indicating investor excitement about a potential new cancer treatment.
Write to Julia Zorthian at email@example.com.